Drugs Made In America Acquisition Corp. (DMAAU) Operating Expenses (2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Operating Expenses came in at $2.1 million in Q4 2025, up 692.36% on a QoQ basis from $263703.0 in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Operating Expenses (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 1 years of Operating Expenses data on file, last reported at $2.1 million in Q4 2025.
- Quarterly Operating Expenses changed N/A year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (changed N/A YoY) and the FY2025 annual result came in at $2.8 million, up 906.28% from the prior year.
- Operating Expenses advanced to $2.1 million in Q4 2025, from $263703.0 in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $2.1 million in Q4 2025 to a low of $131919.0 in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.09 Mn |
| Sep 30, 2025 | 263,703.00 |
| Jun 30, 2025 | 131,919.00 |
| Mar 31, 2025 | 330,925.00 |